{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["berberine", "gut microbiota", "insulin resistance", "polycystic ovary syndrome"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37604463", "DateRevised": {"Year": "2023", "Month": "10", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "08", "Day": "21"}], "Language": ["eng"], "ELocationID": ["10.1111/1440-1681.13814"], "Journal": {"ISSN": "1440-1681", "JournalIssue": {"Volume": "50", "Issue": "11", "PubDate": {"Year": "2023", "Month": "Nov"}}, "Title": "Clinical and experimental pharmacology & physiology", "ISOAbbreviation": "Clin Exp Pharmacol Physiol"}, "ArticleTitle": "Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.", "Pagination": {"StartPage": "835", "EndPage": "843", "MedlinePgn": "835-843"}, "Abstract": {"AbstractText": ["Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese medicinal plants showing a tight correlation with gut microbiota. Polycystic ovary syndrome (PCOS) is a prevalent reproductive and endocrine disorder syndrome among women of childbearing age. Dysbiosis, the imbalance of intestinal microorganisms, is a potential factor that takes part in the pathogenesis of PCOS. Recent evidence indicates that berberine offers promise for treating PCOS. Here, we review the recent research on the interaction between berberine and intestinal microorganisms, including the changes in the structure of gut bacteria, the intestinal metabolites after BBR treatment, and the effect of gut microbiota on the bioavailability of BBR. We also discuss the therapeutic effect of BBR on PCOS in terms of gut microbiota and its potential mechanisms."], "CopyrightInformation": "\u00a9 2023 John Wiley & Sons Australia, Ltd."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China."}, {"Identifier": [], "Affiliation": "Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China."}, {"Identifier": [], "Affiliation": "Shanghai Clinical Research Center for Gynecological Diseases (22MC1940200), Shanghai Urogenital System Diseases Research Center (2022ZZ01012), Shanghai, People's Republic of China."}], "LastName": "Zhu", "ForeName": "Ting-Wei", "Initials": "TW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China."}, {"Identifier": [], "Affiliation": "Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China."}, {"Identifier": [], "Affiliation": "Shanghai Clinical Research Center for Gynecological Diseases (22MC1940200), Shanghai Urogenital System Diseases Research Center (2022ZZ01012), Shanghai, People's Republic of China."}], "LastName": "Li", "ForeName": "Xue-Lian", "Initials": "XL"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Australia", "MedlineTA": "Clin Exp Pharmacol Physiol", "NlmUniqueID": "0425076", "ISSNLinking": "0305-1870"}}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Imenshahidi M, Hosseinzadeh H. Berberis Vulgaris and Berberine: An Update Review. Phytother Res. 2016;30(11):1745-1764."}, {"Citation": "Habtemariam S. Berberine pharmacology and the gut microbiota: a hidden therapeutic link. Pharmacol Res. 2020;155:104722."}, {"Citation": "Pan C, Guo Q, Lu N. Role of gut microbiota in the pharmacological effects of natural products. Evid Based Complement Alternat Med. 2019;2019:2682748."}, {"Citation": "Cheng H, Liu J, Tan Y, Feng W, Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. J Pharm Anal. 2022;12(4):541-555."}, {"Citation": "O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688-693."}, {"Citation": "Gebrayel P, Nicco C, Al Khodor S, et al. Microbiota medicine: towards clinical revolution. J Transl Med. 2022;20(1):111."}, {"Citation": "Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364-379."}, {"Citation": "Okubo H, Nakatsu Y, Kushiyama A, et al. Gut microbiota as a therapeutic target for metabolic disorders. Curr Med Chem. 2018;25(9):984-1001."}, {"Citation": "Fu Y, Wang Y, Wang X, Sun Y, Ren J, Fang B. Responses of human gut microbiota abundance and amino acid metabolism in vitro to berberine. Food Funct. 2022;13(11):6329-6337."}, {"Citation": "Tian Y, Cai J, Gui W, et al. Berberine directly affects the gut microbiota to promote intestinal Farnesoid X receptor activation. Drug Metab Dispos. 2019;47(2):86-93."}, {"Citation": "Zhao JD, Li Y, Sun M, et al. Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. World J Gastroenterol. 2021;27(8):708-724."}, {"Citation": "Yang S, Cao S, Li C, et al. Berberrubine, a Main metabolite of berberine, alleviates non-alcoholic fatty liver disease via modulating glucose and lipid metabolism and restoring gut microbiota. Front Pharmacol. 2022;13:913378."}, {"Citation": "Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015."}, {"Citation": "Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14(3):238."}, {"Citation": "Pu Z, Sun Y, Jiang H, et al. Effects of berberine on gut microbiota in patients with mild metabolic disorders induced by olanzapine. Am J Chin Med. 2021;49(8):1949-1963."}, {"Citation": "Yan S, Chang J, Hao X, et al. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. Phytomedicine. 2022;102:154217."}, {"Citation": "Li J, Li J, Ni J, et al. Berberine relieves metabolic syndrome in mice by inhibiting liver inflammation caused by a high-fat diet and potential association with gut microbiota. Front Microbiol. 2021;12:752512."}, {"Citation": "Xu B, Yan Y, Huang J, Yin B, Pan Y, Ma L. Cortex Phellodendri extract's anti-diarrhea effect in mice related to its modification of gut microbiota. Biomed Pharmacother. 2020;123:109720."}, {"Citation": "Wang Y, Shou JW, Li XY, et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017;70:72-84."}, {"Citation": "Wu M, Yang S, Wang S, et al. Effect of berberine on atherosclerosis and gut microbiota modulation and their correlation in high-fat diet-fed ApoE\u2212/\u2212 mice. Front Pharmacol. 2020;11:223."}, {"Citation": "Yue M, Tao Y, Fang Y, et al. The gut microbiota modulator berberine ameliorates collagen-induced arthritis in rats by facilitating the generation of butyrate and adjusting the intestinal hypoxia and nitrate supply. FASEB J. 2019;33(11):12311-12323."}, {"Citation": "Zeisel SH, Warrier M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annu Rev Nutr. 2017;37:157-181."}, {"Citation": "Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. MBio. 2015;6(2):e02481."}, {"Citation": "Li X, Su C, Jiang Z, et al. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. NPJ Biofilms Microbiomes. 2021;7(1):36."}, {"Citation": "Xie Z, Liu X, Huang X, et al. Remodelling of gut microbiota by berberine attenuates trimethylamine N-oxide-induced platelet hyperreaction and thrombus formation. Eur J Pharmacol. 2021;911:174526."}, {"Citation": "Ma SR, Tong Q, Lin Y, et al. Berberine treats atherosclerosis via a vitamine-like effect down-regulating choline-TMA-TMAO production pathway in gut microbiota. Signal Transduct Target Ther. 2022;7(1):207."}, {"Citation": "Gu S, Cao B, Sun R, et al. A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. Mol Biosyst. 2015;11(2):463-474."}, {"Citation": "Li D, Feng G, Li Y, et al. Benefits of Huang Lian mediated by gut microbiota on HFD/STZ-induced type 2 diabetes mellitus in mice. Front Endocrinol (Lausanne). 2023;14:1120221."}, {"Citation": "Long SL, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017;56:54-65."}, {"Citation": "Sun R, Yang N, Kong B, et al. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway. Mol Pharmacol. 2017;91(2):110-122."}, {"Citation": "Li M, Zhou W, Dang Y, Li C, Ji G, Zhang L. Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice. Biomed Pharmacother. 2020;132:110953."}, {"Citation": "Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech. 2011;12(2):705-711."}, {"Citation": "Liao CP, Liu XC, Dong SQ, et al. Investigation of the metabolites of five major constituents from Berberis amurensis in normal and pseudo germ-free rats. Chin J Nat Med. 2021;19(10):758-771."}, {"Citation": "Du H, Xu T, Yi H, et al. Effect of gut microbiota on the metabolism of chemical constituents of Berberis kansuensis extract based on UHPLC-orbitrap-MS technique. Planta Med. 2022;88(11):933-949."}, {"Citation": "Zhang ZW, Cong L, Peng R, et al. Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota. J Pharm Anal. 2021;11(5):628-637."}, {"Citation": "Feng R, Shou JW, Zhao ZX, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155."}, {"Citation": "Rodriguez Paris V, Wong XYD, Solon-Biet SM, et al. The interplay between PCOS pathology and diet on gut microbiota in a mouse model. Gut Microbes. 2022;14(1):2085961."}, {"Citation": "Yang Z, Fu H, Su H, et al. Multi-omics analyses reveal the specific changes in gut metagenome and serum metabolome of patients with polycystic ovary syndrome. Front Microbiol. 2022;13:1017147."}, {"Citation": "Chen F, Chen Z, Chen M, et al. Reduced stress-associated FKBP5 DNA methylation together with gut microbiota dysbiosis is linked with the progression of obese PCOS patients. NPJ Biofilms Microbiomes. 2021;7(1):60."}, {"Citation": "Jobira B, Frank DN, Pyle L, et al. Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. J Clin Endocrinol Metab. 2020;105(6):e2134-e2144."}, {"Citation": "Lingaiah S, Arffman RK, Morin-Papunen L, Tapanainen JS, Piltonen T. Markers of gastrointestinal permeability and dysbiosis in premenopausal women with PCOS: a case-control study. BMJ Open. 2021;11(7):e045324."}, {"Citation": "Zhao Y, Fu L, Li R, et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012;10:153."}, {"Citation": "de la Cuesta-Zuluaga J, Mueller NT, Alvarez-Quintero R, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2018;11(1):51."}, {"Citation": "Li G, Liu Z, Ren F, et al. Alterations of gut microbiome and fecal fatty acids in patients with polycystic ovary syndrome in Central China. Front Microbiol. 2022;13:911992."}, {"Citation": "Zhang B, Shen S, Gu T, et al. Increased circulating conjugated primary bile acids are associated with hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2019;189:171-175."}, {"Citation": "Giampaolino P, Foreste V, Di Filippo C, et al. Microbiome and PCOS: state-of-art and future aspects. Int J Mol Sci. 2021;22(4):2048."}, {"Citation": "Ye Z, Zhang C, Wang S, et al. Amino acid signatures in relation to polycystic ovary syndrome and increased risk of different metabolic disturbances. Reprod Biomed Online. 2022;44(4):737-746."}, {"Citation": "Paczkowska K, Rachon D, Berg A, et al. Specific alteration of branched-chain amino acid profile in polycystic ovary syndrome. Biomedicine. 2023;11(1):108."}, {"Citation": "Huang J, Liu L, Chen C, Gao Y. PCOS without hyperandrogenism is associated with higher plasma trimethylamine N-oxide levels. BMC Endocr Disord. 2020;20(1):3."}, {"Citation": "Eyupoglu ND, Caliskan Guzelce E, Acikgoz A, et al. Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019;91(6):810-815."}, {"Citation": "Zheng Y, Yu J, Liang C, Li S, Wen X, Li Y. Characterization on gut microbiome of PCOS rats and its further design by shifts in high-fat diet and dihydrotestosterone induction in PCOS rats. Bioprocess Biosyst Eng. 2021;44(5):953-964."}, {"Citation": "Dong S, Jiao J, Jia S, et al. 16S rDNA full-length assembly sequencing technology analysis of intestinal microbiome in polycystic ovary syndrome. Front Cell Infect Microbiol. 2021;11:634981."}, {"Citation": "Huang J, Chen P, Xiang Y, et al. Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells. Int Immunopharmacol. 2022;107:108717."}, {"Citation": "He F, Li Y. The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population. J Ovarian Res. 2021;14(1):50."}, {"Citation": "Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111-128."}, {"Citation": "Martinot E, Sedes L, Baptissart M, et al. Bile acids and their receptors. Mol Aspects Med. 2017;56:2-9."}, {"Citation": "Yang YL, Zhou WW, Wu S, et al. Intestinal Flora is a key factor in insulin resistance and contributes to the development of polycystic ovary syndrome. Endocrinology. 2021;162(10):bpab118."}, {"Citation": "Szmygin H, Lenart-Lipinska M, Szydelko J, Wozniak S, Matyjaszek-Matuszek B. Branched-chain amino acids as a novel biomarker of metabolic disturbances in women with polycystic ovary syndrome-literature review. Ginekol pol. 2022;93(8):665-669."}, {"Citation": "Tremellen K, Pearce K. Dysbiosis of gut microbiota (DOGMA)-a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012;79(1):104-112."}, {"Citation": "Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502-1511."}, {"Citation": "Insenser M, Murri M, Del Campo R, Martinez-Garcia MA, Fernandez-Duran E, Escobar-Morreale HF. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. J Clin Endocrinol Metab. 2018;103(7):2552-2562."}, {"Citation": "Sherman SB, Sarsour N, Salehi M, et al. Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis. Gut Microbes. 2018;9(5):400-421."}, {"Citation": "Fox CW, Zhang L, Sohni A, et al. Inflammatory stimuli trigger increased androgen production and shifts in gene expression in theca-interstitial cells. Endocrinology. 2019;160(12):2946-2958."}, {"Citation": "Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-221."}, {"Citation": "Wang D, Weng Y, Zhang Y, et al. Exposure to hyperandrogen drives ovarian dysfunction and fibrosis by activating the NLRP3 inflammasome in mice. Sci Total Environ. 2020;745:141049."}, {"Citation": "Shen HR, Xu X, Ye D, Li XL. Berberine improves the symptoms of DHEA-induced PCOS rats by regulating gut microbiotas and metabolites. Gynecol Obstet Invest. 2021;86(4):388-397."}, {"Citation": "Crovesy L, Masterson D, Rosado EL. Profile of the gut microbiota of adults with obesity: a systematic review. Eur J Clin Nutr. 2020;74(9):1251-1262."}, {"Citation": "Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020;123(10):1127-1137."}, {"Citation": "Zhao F, Ding X, An M, Zhao Y, Liu J. Effects of berberine on intestinal flora and LPS/NF-kappaB signaling pathway in PCOS rats. J Gansu Agric Univ. 2022;57(3):1-11."}, {"Citation": "Zhang F, Ma T, Cui P, et al. Diversity of the gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacologic effects of Diane-35, probiotics, and berberine. Front Microbiol. 2019;10:175."}, {"Citation": "Li MF, Zhou XM, Li XL. The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2018;2018:2532935."}, {"Citation": "Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes. 2021;13(1):1-24."}, {"Citation": "Liu R, Zhang C, Shi Y, et al. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. 2017;8:324."}, {"Citation": "He Y, Mei L, Wang L, et al. Lactiplantibacillus plantarum CCFM1019 attenuate polycystic ovary syndrome through butyrate dependent gut-brain mechanism. Food Funct. 2022;13(3):1380-1392."}, {"Citation": "Olaniyi KS, Areloegbe SE, Oyeleke MB. Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity. Endocrine. 2022;78(3):628-640."}, {"Citation": "Olaniyi KS, Areloegbe SE. Acetate circumvents impaired metabolic switch in skeletal muscle of letrozole-induced PCOS rat model by suppression of PDK4/NLRP3. Nutrition. 2023;107:111914."}, {"Citation": "Olaniyi KS, Areloegbe SE. Acetate: a therapeutic candidate against renal disorder in a rat model of polycystic ovarian syndrome. J Steroid Biochem Mol Biol. 2023;225:106179."}, {"Citation": "Olaniyi KS, Areloegbe SE. Suppression of PCSK9/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome. Life Sci. 2022;300:120560."}, {"Citation": "Qi X, Yun C, Sun L, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;25(8):1225-1233."}, {"Citation": "Zhao FQ, Zhao Y, Liu JY, Gou YJ, Yang YQ. Effects of berberine on LPS /NF-kappaB and MAPK signaling pathways in PCOS model rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022;38(2):181-186."}, {"Citation": "Song J, Xiao K, Ke YL, et al. Effect of a probiotic mixture on intestinal microflora, morphology, and barrier integrity of broilers subjected to heat stress. Poult Sci. 2014;93(3):581-588."}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2023", "Month": "7", "Day": "3"}, {"Year": "2023", "Month": "4", "Day": "28"}, {"Year": "2023", "Month": "8", "Day": "1"}, {"Year": "2023", "Month": "8", "Day": "22", "Hour": "0", "Minute": "42"}, {"Year": "2023", "Month": "8", "Day": "22", "Hour": "0", "Minute": "42"}, {"Year": "2023", "Month": "8", "Day": "21", "Hour": "19", "Minute": "36"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37604463", "10.1111/1440-1681.13814"]}}], "PubmedBookArticle": []}